Literature DB >> 15755971

Aromatase inhibitors for breast cancer prevention.

Jack Cuzick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15755971     DOI： 10.1200/JCO.2005.11.027

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  28 in total

Review 1.  Molecular therapy of breast cancer: progress and future directions.

Authors:  Sheng-Xiang Lin; Jiong Chen; Mausumi Mazumdar; Donald Poirier; Cheng Wang; Arezki Azzi; Ming Zhou
Journal:  Nat Rev Endocrinol       Date:  2010-07-20       Impact factor: 43.330

Review 2.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

3.  Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Authors:  Laura Reimers; Katherine D Crew
Journal:  Curr Breast Cancer Rep       Date:  2012-09-01

4.  EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen.

Authors:  Aleksandra Sobczyńska-Rak; Beata Żylińska; Łukasz Jarosz; Adam Brodzki; Marcin Tatara
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

5.  Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.

Authors:  Pascale This; Anne de la Rochefordière; Alexia Savignoni; Marie Christine Falcou; Anne Tardivon; Fabienne Thibault; Séverine Alran; Virgine Fourchotte; Alfred Fitoussi; Benoit Couturaud; Sylvie Dolbeault; Remy J Salmon; Brigitte Sigal-Zafrani; Bernard Asselain; Dominique Stoppa-Lyonnet
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

6.  Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women.

Authors:  Christine M Friedenreich; Christy G Woolcott; Anne McTiernan; Rachel Ballard-Barbash; Rollin F Brant; Frank Z Stanczyk; Tim Terry; Norman F Boyd; Martin J Yaffe; Melinda L Irwin; Charlotte A Jones; Yutaka Yasui; Kristin L Campbell; Margaret L McNeely; Kristina H Karvinen; Qinggang Wang; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

Review 7.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

8.  The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.

Authors:  Abhijit Mazumdar; Daniel Medina; Francis S Kittrell; Yun Zhang; Jamal L Hill; David E Edwards; Reid P Bissonnette; Powel H Brown
Journal:  Cancer Prev Res (Phila)       Date:  2012-08-27

Review 9.  The invisible arm of immunity in common cancer chemoprevention agents.

Authors:  Edmond Marzbani; Carol Inatsuka; Hailing Lu; Mary L Disis
Journal:  Cancer Prev Res (Phila)       Date:  2013-08

10.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Authors:  Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.